Constellation Pharmaceuticals to Participate in Investor Conference

Rhea-AI Summary

Constellation Pharmaceuticals (Nasdaq: CNST) will participate in the Jefferies Virtual Healthcare Conference on June 2, 2020, at 2:30 PM EDT. CEO Jigar Raythatha will present, and a live audio webcast will be accessible on the company’s investor relations website. The replay will be available for 30 days post-event. Constellation focuses on developing epigenetic therapeutics to address unmet medical needs in cancer treatment, particularly through its BET inhibitor CPI-0610 and EZH2 inhibitors CPI-1205 and CPI-0209.

CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference.  Jigar Raythatha, CEO, will present at the Jefferies Virtual Healthcare Conference at 2:30 PM EDT on June 2.  A live audio webcast of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events.  The audio webcast replay will be available for 30 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer.  The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers.  The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates. 

Contact

Kia Khaleghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com 

Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
ron.aldridge@constellationpharma.com 

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com 

FAQ

When is Constellation Pharmaceuticals presenting at the Jefferies Virtual Healthcare Conference?

Constellation Pharmaceuticals will present on June 2, 2020, at 2:30 PM EDT.

Who will represent Constellation Pharmaceuticals at the conference?

CEO Jigar Raythatha will represent Constellation Pharmaceuticals at the event.

How can I access the presentation from Constellation Pharmaceuticals?

The presentation can be accessed via a live audio webcast on Constellation's investor relations website.

What are the main therapeutic focuses of Constellation Pharmaceuticals?

Constellation Pharmaceuticals focuses on developing therapeutics targeting epigenetics for cancer treatment, including products like CPI-0610 and EZH2 inhibitors.

For how long will the webcast replay be available?

The audio webcast replay will be available for 30 days following the live presentation.